News | November 12, 2007

Edwards Acquires CardioVations Line for $27 Million

November 13, 2007 - Edwards Lifesciences Corp., a heart valve provider, will acquire certain assets of the CardioVations Division of Ethicon Inc. for $27 million to expand its portfolio of minimally invasive surgical offerings.

CardioVations’ product line includes the PORT-ACCESS products, such as the proprietary EndoCPB and EndoDirect systems for minimally invasive heart valve surgery, including soft tissue retractors, venous and arterial cannulae, vent and coronary sinus catheters and reusable instruments for performing port-access cardiac valve procedures. The CardioVations product line is expected to generate sales of more than $20 million in 2008.
The purchase price of approximately $27 million includes inventory, related intellectual property rights and the assumption of certain liabilities. It is not expected to have an impact on earnings in 2008 and will be accretive thereafter. The acquisition is anticipated to close by the end of 2007, subject to customary closing conditions.
The PORT-ACCESS system allows surgeons to perform minimally invasive heart valve operations through small openings, or “ports,” in the spaces between the ribs, rather than opening a patient’s chest.

For more information: www.edwards.com

Related Content

The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect

The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. 

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart
The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020. #TCT #TCT2020 #TCTconnect

The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020.

Feature | Heart Valve Technology | October 15, 2020
October 15, 2020 – The SCOPE II trial comparing the Boston Scientific Acurate neo vs.
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture. #TCT2020 #TCTconnect

An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture.

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The...
Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 

Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 

News | Heart Valve Technology | October 14, 2020
October 14, 2020 — Medtronic announced it is starting a randomized, head-to-head study comparing two transcatheter ao
The Cardiac Dimensions Carillon Mitral Contour System, a transcatheter device used to treat functional mitral regurgitation (FMR) in patients with heart failure.
News | Heart Valve Technology | October 02, 2020
October 2, 2020 — Cardiac Dimensions announced the company has closed a $17.5 million Series C financing that will be
Boston Scientific launched the Acurate neo2 transcatheter aortic valve replacement (TAVR) system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original Acurate neo platform. Compared to the previous generation device, the Acurate neo2 valve system also has an expanded indication for patients with aortic stenosis. #TAVR #TAVI
News | Heart Valve Technology | September 29, 2020
September 29, 2020 — Boston Scientific launched the...
National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early
News | Heart Valve Technology | August 12, 2020
August 12, 2020 — A national survey conducted by the patient advocacy group...